Latest news with #Trial
Yahoo
a day ago
- Entertainment
- Yahoo
Johnny Depp Says He Has 'No Regrets' About Amber Heard Trial & Was A 'Crash Test Dummy For #MeToo'
In a sprawling interview with The Times U.K., Johnny Depp claimed he was a 'crash test dummy for #MeToo,' reflecting on his protracted legal battle with actress and ex-wife Amber Heard. 'My comeback? Honestly? I didn't go anywhere,' he said. 'If I had the chance to split I would never come back.' More from Deadline Sick Juror Throws Sean Combs Trial Off Tight Schedule; No Decision Yet If Diddy Will Testify Tyler Perry Slams $260M Sexual Assault Suit By 'The Oval' Actor As A "Scam" Another Harvey Weinstein Rape Retrial Could Start This Fall, Judge Says; Current Case Ends In Mistrial As Jury Foreman Won't Return To Deliberations - Update The Pirates of the Caribbean star, who classified his ousting from Hollywood as a 'boycott,' praised the San Sebastián International Film Festival for sticking with him through 'all the hit pieces, the bullsh–.' In 2021, the fest awarded him the prestigious Donostia, its highest accolade, and last year, his second directorial effort, Modi: Three Days on the Wing of Madness, garnered a long-standing ovation by the crowd. 'No, I have no regrets about anything — because, truly, what can we do about last week's dinner? Not a f—ing thing,' he said of the much-publicized court trial with Heard. In 2022, Depp and Heard engaged in a contentious court battle during which a jury unanimously found he was defamed. After Heard filed an appeal of the verdict, the two announced separately that the case had been settled with the money paid by Heard going to charity. The case stemmed from a 2018 Washington Post op-ed in which Heard said she was a survivor of domestic violence without mentioning Depp's name. Throughout the media circus that ensued during the live-streamed trial, Heard — who wields considerably less power as a woman who is not as well-known nor cherished as veteran Depp — was largely raked over the coals both online and by Depp's fans who lined the doors outside the courtroom, receiving death threats. Studies conducted by a research firm also indicated the overwhelming hatred she experienced on social media was not entirely human-generated. The Virginia battle also followed a separate libel case in the U.K. over The Sun's calling Depp a 'wife beater.' The judge sided with the publication in 2020, after which Depp was asked to resign from Warner Bros.' Fantastic Beasts franchise, with the judge finding that the 'great majority of alleged assaults of Ms. Heard by Mr. Depp have been proved.' When asked why he pursued the public trial in the U.S., Depp answered: 'Look, it had gone far enough. I knew I'd have to semi-eviscerate myself. Everyone was saying, 'It'll go away!' But I can't trust that. What will go away? The fiction pawned around the f—ing globe? No it won't. If I don't try to represent the truth it will be like I've actually committed the acts I am accused of. And my kids will have to live with it. Their kids. Kids that I've met in hospitals. So the night before the trial in Virginia I didn't feel nervous. If I don't have to memorize lines, if you're just speaking the truth? Roll the dice.' He continued, 'Look, none of this was going to be easy, but I didn't care. I thought, 'I'll fight until the bitter f—ing end.' And if I end up pumping gas? That's all right. I've done that before.' Depp also claimed his experience predated #MeToo, and that's why people failed to support him. However, activist Tarana Burke's hashtag and movement were founded in 2006, later moving to the entertainment industry space circa 2017, the same year the New York Times and The New Yorker published exposés on now-disgraced mogul Harvey Weinstein. 'I'll tell you what hurts. There are people, and I'm thinking of three, who did me dirty. Those people were at my kids' parties. Throwing them in the air. And, look, I understand people who could not stand up [for me] because the most frightening thing to them was making the right choice,' he said. 'I was pre-#MeToo. I was like a crash test dummy for #MeToo. It was before Harvey Weinstein. And I sponged it, took it all in. And so I wanted from the hundreds of people I've met in that industry to see who was playing it safe. Better go woke!' Since 2022, the actor hasn't really gone gently into that good night — hence the disagreement with the term 'comeback.' That year, he made a surprise appearance at the MTV Video Music Awards; later on, he embarked on a 2023 European tour with band Hollywood Vampires and was seen in Savage X Fenty's fashion show. More recently, he is set to reunite with Pirates of the Caribbean co-star Penelope Cruz in Lionsgate's upcoming Day Drinker, also featuring Madelyn Cline. Additionally, filming for Terry Gilliam's Carnival: At the End of Days, opposite Adam Driver, Jeff Bridges and Jason Momoa was scheduled to commence in April. Best of Deadline Sean 'Diddy' Combs Sex-Trafficking Trial Updates: Cassie Ventura's Testimony, $10M Hotel Settlement, Drugs, Violence, & The Feds A Full Timeline Of Blake Lively & Justin Baldoni's 'It Ends With Us' Feud In Court, Online & In The Media 'Poker Face' Season 2 Guest Stars: From Katie Holmes To Simon Hellberg
CTV News
13-06-2025
- CTV News
Closing arguments in Adam Drake trial underway
Closing arguments in Adam Drake trial underway Crown prosecutors told a jury Adam Drake should be found guilty of second-degree murder in the death of Pat Stay.
Yahoo
21-05-2025
- Health
- Yahoo
EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical's DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX® compared to DES— —Significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with DynamX® compared to DES— Paris – May 21, 2025 – Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced three-year results from the large 445-patient BIOADAPTOR Randomized Controlled (1:1) Trial (RCT), comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute OnyxTM Drug-Eluting Stent (DES) from 34 centers in Japan, Europe, and New Zealand. The results demonstrate sustained very low adverse events and durability of clinical outcomes with DynamX® bioadaptor in target lesion failure (TLF) and Cardiovascular Death (CVD) compared to non-plateauing increase in adverse events in the DES arm. The data were presented at a late-breaking clinical session during the EuroPCR 2025 conference in Paris. Clinical results show sustained significant reduction of device-oriented adverse events with DynamX® bioadaptor over the drug-eluting stent at three years: Significant reduction in TLF rate (2.7% versus 7.2%; p=0.030) demonstrating the durability of DynamX® treatment through three years of follow-up. The significant reduction in TLF was driven by low adverse events across all components of the composite endpoint with DynamX® compared to DES, respectively: Significantly lower Cardiovascular Death (0.5% versus 3.2%, p=0.033) Target Vessel Myocardial Infarction (0.9% versus 1.8%) Ischemia-Driven Target Lesion Revascularization (1.4% versus 2.7%) Reduction in adverse events amplified in Left Anterior Descending (LAD) artery lesions: Significantly lower TLF rate in LAD lesions (2.7% versus 10.6%; p=0.019) consistent with bioadaptor mechanism of action of restoring vessel function in this hemodynamically critical coronary vessel as reported previously in the imaging subgroup at 12 months1. 'These three-year results from the BIOADAPTOR RCT demonstrate that DynamX bioadaptor provides for a new class of treatment—with significant clinical benefit from six months when the bioadaptor mechanism of action is activated and sustained through long-term follow-up, including the hard clinical endpoint of cardiovascular death,' said Shigeru Saito, M.D., director of the Division of Cardiology and Catheterization Laboratory at Shonan Kamakura General Hospital in Kamakura, Japan. 'We also see the heightened importance of restoring hemodynamic modulation in the LAD vessel demonstrated by the large difference in clinical events in LAD lesions between the two treatment arms.' The DynamX bioadaptor is differentiated from the current therapies, having a novel mechanism of action designed to return vessel health through three distinct phases of adapting in the body to restore vessel biology. In the locked phase during the implant, the bioadaptor opens the artery and restores blood flow. Unique to bioadaptor, after six months the implant unlocks, separates into three helical strands, releasing the vessel and providing dynamic support to maintain the established blood flow lumen. The continued adaptive dynamic support helps return vessel hemodynamic modulation through restoration of pulsatility and adaptive blood flow volume and has also shown evidence of plaque stabilization and regression in the lesion. 'With these results, we are pleased to demonstrate that restoring hemodynamic modulation of the artery translates to lasting clinical outcomes, elevating the level of care for patients,' said Motasim Sirhan, CEO of Elixir Medical. 'With the three-year BIOADAPTOR-RCT data presented today, and the results from the 2,400 patient INIFINITY-SWEDEHEART RCT published in The Lancet, we have shown consistently across multiple trials significantly lower, plateauing clinical events after six months with DynamX® bioadaptor compared to DES, validating the benefit of our transformative technology.' About BIOADAPTOR RCT TrialThe BIOADAPTOR RCT is an international, single-blind, randomized controlled (1:1) trial comparing a sirolimus-eluting bioadaptor with a contemporary zotarolimus-eluting stent in 445 patients in 34 centers in Japan, Europe, and New Zealand. Both arms had large randomized multi-modality imaging subgroups of 50 patients each to document standard effectiveness benchmarks of establishing and maintaining artery flow lumen measured by percent diameter stenosis (%DS) and late lumen loss (LLL), and the new effectiveness benchmarks of restoring artery hemodynamic modulation, including pulsatility, vessel compliance, adaptive flow volume, and plaque stabilization and regression. Clinical follow-up will continue through five years. BIOADAPTOR RCT trial is the third trial of Elixir Medical's robust DynamX® bioadaptor clinical evidence program consisting of nine company-sponsored and investigator-initiated studies involving over 9,000 patients, including INFINITY SWEDEHEART RCT (n=2400) and a global BIO-RESTORE registry with a target enrollment of up to 5,000 patients. About DynamX Coronary Bioadaptor SystemThe DynamX® bioadaptor is the first coronary implant technology designed to restore coronary artery hemodynamic modulation as demonstrated by restored vessel pulsatility, compliance, and adaptive increase in blood flow volume, and providing plaque stabilization and regression. With its unique mechanism of action (MOA), it addresses the shortcomings of drug-eluting stents and bioresorbable scaffolds (BRS) with remarkably low clinical event rates that showed a plateau from six months through three-year clinical follow-up. The DynamX® Coronary Bioadaptor System is CE-marked. The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device. Limited by Federal (or United States) law to investigational use. About Elixir MedicalElixir Medical Corporation, a privately held company based in Milpitas, California, develops disruptive platforms to treat coronary and peripheral artery disease. Our transformative technologies have multiple applications across the cardiovascular space capable of delivering improved clinical outcomes for millions of patients. Elixir Medical was named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025. Visit us at and on LinkedIn. Media ContactRichard LaermerRLM PRelixir@ 741-5106 X 216 1 Saito S et al. 12-Months Outcomes BIODAPTOR-RCT. The Lancet eClinicalMedicine. 2023;65: in to access your portfolio
Yahoo
21-05-2025
- Health
- Yahoo
EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical's DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX® compared to DES— —Significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with DynamX® compared to DES— Paris – May 21, 2025 – Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced three-year results from the large 445-patient BIOADAPTOR Randomized Controlled (1:1) Trial (RCT), comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute OnyxTM Drug-Eluting Stent (DES) from 34 centers in Japan, Europe, and New Zealand. The results demonstrate sustained very low adverse events and durability of clinical outcomes with DynamX® bioadaptor in target lesion failure (TLF) and Cardiovascular Death (CVD) compared to non-plateauing increase in adverse events in the DES arm. The data were presented at a late-breaking clinical session during the EuroPCR 2025 conference in Paris. Clinical results show sustained significant reduction of device-oriented adverse events with DynamX® bioadaptor over the drug-eluting stent at three years: Significant reduction in TLF rate (2.7% versus 7.2%; p=0.030) demonstrating the durability of DynamX® treatment through three years of follow-up. The significant reduction in TLF was driven by low adverse events across all components of the composite endpoint with DynamX® compared to DES, respectively: Significantly lower Cardiovascular Death (0.5% versus 3.2%, p=0.033) Target Vessel Myocardial Infarction (0.9% versus 1.8%) Ischemia-Driven Target Lesion Revascularization (1.4% versus 2.7%) Reduction in adverse events amplified in Left Anterior Descending (LAD) artery lesions: Significantly lower TLF rate in LAD lesions (2.7% versus 10.6%; p=0.019) consistent with bioadaptor mechanism of action of restoring vessel function in this hemodynamically critical coronary vessel as reported previously in the imaging subgroup at 12 months1. 'These three-year results from the BIOADAPTOR RCT demonstrate that DynamX bioadaptor provides for a new class of treatment—with significant clinical benefit from six months when the bioadaptor mechanism of action is activated and sustained through long-term follow-up, including the hard clinical endpoint of cardiovascular death,' said Shigeru Saito, M.D., director of the Division of Cardiology and Catheterization Laboratory at Shonan Kamakura General Hospital in Kamakura, Japan. 'We also see the heightened importance of restoring hemodynamic modulation in the LAD vessel demonstrated by the large difference in clinical events in LAD lesions between the two treatment arms.' The DynamX bioadaptor is differentiated from the current therapies, having a novel mechanism of action designed to return vessel health through three distinct phases of adapting in the body to restore vessel biology. In the locked phase during the implant, the bioadaptor opens the artery and restores blood flow. Unique to bioadaptor, after six months the implant unlocks, separates into three helical strands, releasing the vessel and providing dynamic support to maintain the established blood flow lumen. The continued adaptive dynamic support helps return vessel hemodynamic modulation through restoration of pulsatility and adaptive blood flow volume and has also shown evidence of plaque stabilization and regression in the lesion. 'With these results, we are pleased to demonstrate that restoring hemodynamic modulation of the artery translates to lasting clinical outcomes, elevating the level of care for patients,' said Motasim Sirhan, CEO of Elixir Medical. 'With the three-year BIOADAPTOR-RCT data presented today, and the results from the 2,400 patient INIFINITY-SWEDEHEART RCT published in The Lancet, we have shown consistently across multiple trials significantly lower, plateauing clinical events after six months with DynamX® bioadaptor compared to DES, validating the benefit of our transformative technology.' About BIOADAPTOR RCT TrialThe BIOADAPTOR RCT is an international, single-blind, randomized controlled (1:1) trial comparing a sirolimus-eluting bioadaptor with a contemporary zotarolimus-eluting stent in 445 patients in 34 centers in Japan, Europe, and New Zealand. Both arms had large randomized multi-modality imaging subgroups of 50 patients each to document standard effectiveness benchmarks of establishing and maintaining artery flow lumen measured by percent diameter stenosis (%DS) and late lumen loss (LLL), and the new effectiveness benchmarks of restoring artery hemodynamic modulation, including pulsatility, vessel compliance, adaptive flow volume, and plaque stabilization and regression. Clinical follow-up will continue through five years. BIOADAPTOR RCT trial is the third trial of Elixir Medical's robust DynamX® bioadaptor clinical evidence program consisting of nine company-sponsored and investigator-initiated studies involving over 9,000 patients, including INFINITY SWEDEHEART RCT (n=2400) and a global BIO-RESTORE registry with a target enrollment of up to 5,000 patients. About DynamX Coronary Bioadaptor SystemThe DynamX® bioadaptor is the first coronary implant technology designed to restore coronary artery hemodynamic modulation as demonstrated by restored vessel pulsatility, compliance, and adaptive increase in blood flow volume, and providing plaque stabilization and regression. With its unique mechanism of action (MOA), it addresses the shortcomings of drug-eluting stents and bioresorbable scaffolds (BRS) with remarkably low clinical event rates that showed a plateau from six months through three-year clinical follow-up. The DynamX® Coronary Bioadaptor System is CE-marked. The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device. Limited by Federal (or United States) law to investigational use. About Elixir MedicalElixir Medical Corporation, a privately held company based in Milpitas, California, develops disruptive platforms to treat coronary and peripheral artery disease. Our transformative technologies have multiple applications across the cardiovascular space capable of delivering improved clinical outcomes for millions of patients. Elixir Medical was named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025. Visit us at and on LinkedIn. Media ContactRichard LaermerRLM PRelixir@ 741-5106 X 216 1 Saito S et al. 12-Months Outcomes BIODAPTOR-RCT. The Lancet eClinicalMedicine. 2023;65: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Health
- Yahoo
Watch live: The Hill Talks – Breaking Down Financial Barriers to Clinical Trial Participation
Clinical trials are essential for evaluating potential new treatments, advancing the standard of care, and improving patient outcomes, yet only about five percent of Americans participate in them. As it stands, patients from lower-income and rural communities often face substantial economic barriers to participation, including lost wages, time, and out-of-pocket costs for transportation and lodging. What can Congress do to make clinical trials more accessible to patients? What are the biggest barriers to participation? And what does this all mean for the future of drug development? Join us for The Hill Talks: Breaking Down Financial Barriers to Clinical Trial Participation, a bipartisan program examining this issue with lawmakers and patient advocates with a critical focus on health equity. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
